SomaServe's PolyNaut platform addresses the ‘delivery problem’. Reaching the site of action is one of the most pressing challenges in the advancement of gene therapy and the development of protein therapeutics for intracellular targets. Using polyNaut technology we are uniquely able to address the shortcomings of viral or lipid-based delivery technologies by encapsulating a range of therapeutic modalities into polymer nanovesicles that can penetrate the blood brain barrier effectively and selectively target different tissues and cell types. Through partnerships we are deploying PolyNaut to develop a next generation of gene therapies and intracellular proteins in oncology, immunology and CNS disorders.